Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:
- Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00)
- Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56)
- Biomarker assessment approach and treatment selection (10:50)